Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

This study has been terminated.

( Failure to demonstrate a tolerable dose that had potential for efficacy. )

Study NCT00779480 Information provided by Kyowa Hakko Kirin Pharma, Inc.

First Received: October 22, 2008 Last Updated: May 18, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	December 2010
Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)